Home Newsfeeds Taiwan Semiconductor Keeps Fab Utilization Rate at 70% or Higher

Taiwan Semiconductor Keeps Fab Utilization Rate at 70% or Higher

-DigiTimes https://www.digitimes.com/news/a20230308PD216/3nm-5nm-7nm-tsmc.html

byCharles Gross

March 9, 2023

1 minute read

-DigiTimes

https://www.digitimes.com/news/a20230308PD216/3nm-5nm-7nm-tsmc.html

JP Morgan Downgrades Royal Caribbean Gr to Underweight, Lowers Price Target to $47

By Benzinga Newsdesk

December 6, 11:18 AM

JP Morgan analyst Daniel Adam downgrades Royal Caribbean Gr (NYSE:RCL) from Overweight to Underweight and lowers the price target from $106 to $47.

RCL

News

Nikola And FirstElement Fuel Forge 10-Year Strategic Partnership To Advance Hydrogen Fueling Infrastructure

By Benzinga Newsdesk

December 20, 9:06 AM

FirstElement Fuel named authorized Fueling Solutions Partner for Nikola Class 8 hydrogen fuel cell electric trucksPHOENIX, Dec. 20, 2023 /PRNewswire/ -- Nikola Corporation (NASDAQ:NKLA), a global leader in

NKLA

4DMT Gains Alignment With FDA On Plan To Lift Clinical Hold On Phase 1/2 INGLAXA Clinical Trial For 4D-310 For Fabry Disease Cardiomyopathy

By Benzinga Newsdesk

October 30, 8:13 AM

Initiated single non-human primate (NHP) safety study evaluating intravenous 4D-310 combined with rituximab/sirolimus (R/S) immunosuppressive regimenAmended INGLAXA protocol to minimize risk of atypical hemolytic uremic

FDMT

News

Sanofi, DNDi And The HAT-r-ACC Consortium Announces That European Medicines Agency Has Given Positive Opinion To Fexinidazole Winthrop As First Oral Treatment Of Acute Form Of Sleeping Sickness Found In East And Southern Africa

By Benzinga Newsdesk

December 15, 3:37 AM

EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa Paris, Geneva and Nairobi. December 15, 2023. Sanofi,

SNY

Taiwan Semiconductor Keeps Fab Utilization Rate at 70% or Higher

Related Posts

JP Morgan Downgrades Royal Caribbean Gr to Underweight, Lowers Price Target to $47

Nikola And FirstElement Fuel Forge 10-Year Strategic Partnership To Advance Hydrogen Fueling Infrastructure

4DMT Gains Alignment With FDA On Plan To Lift Clinical Hold On Phase 1/2 INGLAXA Clinical Trial For 4D-310 For Fabry Disease Cardiomyopathy

Sanofi, DNDi And The HAT-r-ACC Consortium Announces That European Medicines Agency Has Given Positive Opinion To Fexinidazole Winthrop As First Oral Treatment Of Acute Form Of Sleeping Sickness Found In East And Southern Africa